The latest biotech news

News and Trends 22 Mar 2017

What’s the Gold Standard for Therapeutic Antibodies?

Are fully human antibodies the new gold standard in therapeutic innovation? If you want to upgrade, here’s where to find them. If you’re curious about the future of antibody development, look no further than Humira. This monoclonal antibody (mAb) for various inflammatory diseases soared to become the best-selling biological in 2016. Humira is a fully human […]

March 22, 2017 - 4 minutesmins - By External Contributor

News and Trends 21 Mar 2017

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Minoryx Therapeutics has successfully completed a Phase I trial for its lead compound MIN-102 targeting X-linked adrenoleukodystrophy (X-ALD). The Spanish biotech Minoryx is specialized on orphan diseases and its lead program is a PPAR-gamma agonist, MIN-102, which is in development for X-ALD. The company now announced the successful results of its Phase I trial with MIN-102 revealing the […]

March 21, 2017 - 2 minutesmins - By Melanie De Almeida

Galecto Biotech BMS TD139 Phase Ia IIb 1

News and Trends 20 Mar 2017

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option of take over the biotech. In 2014, Denmark’s Galecto Biotech has signed an option agreement with US-based pharma Bristol-Myers Squibb (BMS) for its lead asset TD139, which is under development for the treatment of pulmonary […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 20 Mar 2017

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Cerenis therapeutic’s lead candidate CER-001 has failed Phase II for the treatment of patients with post-acute coronary syndrome (ACS). The French-based Biotech Cerenis is developing therapies for the treatment of cardiovascular and metabolic diseases. The company now presented data on its lead candidate CER-001, which was investigated in a Phase II study for the treatment of patients with post-acute […]

March 20, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 18 Mar 2017

Wellcome Image Awards: These are the Best Biology Images of the Year

The UK’s Wellcome trust has selected 22 pictures and images that capture the wonders of the life sciences. They’re now on exhibition in the UK and Ireland. The Wellcome Image Awards celebrates this year 20 years of bringing us the best biology images around the world. The awards are destined to visual masterpieces that communicate key aspects […]

March 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Circassia failure AstraZeneca deal cover

News and Trends 17 Mar 2017

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

After the big disaster with its cat allergy vaccine, Circassia closes a €214M deal to acquire rights from two AstraZeneca products for pulmonary disease. Circassia could not beat the placebo in a Phase III trial for cat allergy last year, which immediately drove its stock down by 65% and led to the halt of clinical […]

March 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Mar 2017

This French Startup is Paving the way for Bioplastics from Milk

Can we make plastics out of milk byproducts? The startup Lactips, based near Lyon, is getting ready to make this special kind of bioplastic a commercial reality with its first application, wrapping for detergents. Pun intended: Lactips’ motto is “the milky way of plastics,” and that’s what the startup has been developing since its foundation in […]

March 17, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Mar 2017

Researchers Develop New Virus to Selectively Attack Tumor Cells

Researchers from Barcelona have developed a new genetically engineered oncolytic virus, which can selectively infect and kill tumor cells. Eneko Villanueva and colleagues from the IDIBAPS Biomedical Research Institute and the Institute for Research in Biomedicine (IRB Barcelona) have engineered a virus that infects tumor cells without affecting healthy tissues. Their new cancer therapy approach is based […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

UK Immunotherapy Biotech raises Massive Funding in Series C

The UK biotech Cell Medica picked up a massive €69M (£60M) in its recent Series C funding round to advance its cancer immunotherapy programs. Cell Medica is a clinical stage company developing cell-based therapies to treat cancer. With the aim of advancing the clinical development of its immunotherapies, the company was able to raise an impressive […]

March 16, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 16 Mar 2017

What’s Berlin’s Secret to Success in Biotech & Digital Health?

Berlin is a creative crossroads not just for arts but also life science. A variety of players in academia, industry, and startups make the ecosystem blossom. To those who know Berlin as a creative hub, it might come as a surprise that life science is one of the city’s industrial pillars. The German capital region […]

March 16, 2017 - 8 minutesmins - By External Contributor

News and Trends 15 Mar 2017

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

French researchers have found a protein only expressed in HIV-infected reservoir cells, paving the way for an HIV cure that completely eliminates the virus. Researchers from the Institut de Génétique Humaine (IGH) at Montpellier University, France, have discovered a protein, CD32a, that is only present on the surface of CD4 T cells infected with dormant HIV. This […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Allergan Editas Medicine CRISPR eye disease

News and Trends 15 Mar 2017

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Allergan has signed a deal with Editas Medicine to access its CRISPR technology and license up to five of its programs in ocular disease. The Irish Allergan has a certain tendency to go on shopping sprees. Its latest deal is a research and development alliance with the American Editas Medicine, which is on the side of […]

March 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

What’s the Gold Standard for Therapeutic Antibodies?

A Potential First Treatment for a Rare Genetic Disease clears Phase I

Will BMS Take Over a Danish Biotech in a Massive €400M Deal?

French Biotech fails Second Phase II Trial for Cardiovascular Disease

Wellcome Image Awards: These are the Best Biology Images of the Year

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

This French Startup is Paving the way for Bioplastics from Milk

Researchers Develop New Virus to Selectively Attack Tumor Cells

UK Immunotherapy Biotech raises Massive Funding in Series C

What’s Berlin’s Secret to Success in Biotech & Digital Health?

France Closes in on an HIV Cure by Detecting Cells with Dormant Viruses

Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!